Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 10/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 8/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18791928 | 1.00 | ACSS2 (0.38) | ACSS2MEN1KMT2AMCHR1IDH1 | |
| SCHEMBL18791929 | 1.00 | ACSS2 (0.38) | ACSS2MEN1KMT2AMCHR1IDH1 | |
| SCHEMBL18779281 | 0.89 | IDH1 (0.37) | MEN1KMT2AMCHR1IDH1 | |
| SCHEMBL26008057 | 0.89 | ACSS2 (0.32) | ACSS2MEN1KMT2A | |
| SCHEMBL30315331 | 0.89 | BRD4 (0.38) | MEN1KMT2AMCHR1IDH1 | |
| SCHEMBL21354683 | 0.89 | BRD4 (0.38) | MEN1KMT2AMCHR1IDH1 | |
| SCHEMBL18791934 | 0.88 | CSNK1D (0.39) | ACSS2MCHR1 | |
| SCHEMBL20111376 | 0.88 | CSNK1D (0.39) | ACSS2MCHR1 | |
| SCHEMBL18791666 | 0.88 | CSNK1D (0.39) | ACSS2MCHR1 | |
| SCHEMBL21354586 | 0.86 | MCHR1 (0.37) | MEN1KMT2AMCHR1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062389-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | BOZIK MICHAEL E (US) | 2026-03-05 | — | — | US | disclosed |
| US-12286408-B2 | KV7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-04-29 | — | — | US | disclosed |
| US-20240002349-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2024-01-04 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| US-11261162-B2 | KV7 channel activators compositions and methods of use | KNOPP BIOSCIENCES, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KNOPP BIOSCIENCES LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KNOPP BIOSCIENCES LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2020-02-27 | — | — | US | disclosed |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2019-09-19 | — | — | US | disclosed |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2019-09-19 | — | — | US | disclosed |
| WO-2018081825-A1 | BENZOIMIDAZOL-1, 2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261162-B2 | KV7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885MEN1 1284/4885KMT2A 736/4885 |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885MEN1 1284/4885KMT2A 736/4885 |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885MEN1 1284/4885KMT2A 736/4885 |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885MEN1 1284/4885KMT2A 736/4885 |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885MEN1 1284/4885KMT2A 736/4885 |
| US-20260062389-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNH3, KCNA3 | ACSS2 3238/4885MEN1 1825/4885KMT2A 1606/4885 |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885MEN1 1284/4885KMT2A 736/4885 |
| US-12286408-B2 | KV7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885MEN1 1284/4885KMT2A 736/4885 |
| US-20240002349-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885MEN1 1284/4885KMT2A 736/4885 |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | ACSS2 928/4885MEN1 2929/4885KMT2A 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.